Internal Medicine, Medical Oncology · Aurora, CO
NPI
1336239912
Since 2006
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
12605 E 16th Ave
Aurora, CO, 80045
Phone (720) 848-0000
Groups this clinician bills Medicare through
Medicare paid, 2024
$26K
234 services
Medicare patients, 2024
65
Average age 72
Drug cost, 2024
$843K
201 prescriptions
Company payments, 2025
$80K
From 20 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by David Camidge was code 99215 (office e&m - established), 178 times for 54 patients. In total David Camidge billed 234 services in 6 codes, and Medicare paid $26K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2011-01-04.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99215 Office E&M - Established | Facility | 178 | 54 | $110.17 | $20K |
| 99215 Office E&M - Established | Office | 32 | 11 | $121.73 | $3,895 |
| 99205 Office E&M - New | Facility | 14 | 14 | $143.37 | $2,007 |
By year: 2022 $24K for 213 services; 2023 $24K for 215 services; 2024 $26K for 234 services.
Medicare prescription drug claims, 2024
In 2024, the drug David Camidge prescribed most often to Medicare patients was Dexamethasone, with 42 prescriptions and refills. In total David Camidge wrote 201 Medicare prescriptions that cost $843K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Dexamethasone Generic | 42 | 44 | 11 | $284 |
| Alecensa Alectinib Hcl | 28 | 28 | Under 11 | $378K |
| Prochlorperazine Maleate Generic | 17 | 17 | Under 11 | $163 |
| Alunbrig Brigatinib | 14 | 14 | Under 11 | $313K |
| Ondansetron Hcl Generic | 12 | 12 | Under 11 | $70.7 |
Brand drugs: 67 claims; generic drugs: 134 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid David Camidge $80K ($73K in general payments such as food, travel and fees and $7,436 for research) from 20 companies. The largest payer was Merck Sharp & Dohme LLC with $20K.
| Company | Payments | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC MRK | 11 | $20K |
| Abbvie Inc. ABBV | 7 | $11K |
| Janssen Research & Development, LLC JNJ | 5 | $9,038 |
| Taiho Oncology, Inc. 4578.T | 3 | $8,795 |
| Pfizer Inc. PFE | 3 | $4,350 |
| Genzyme Corporation SNY | 4 | $3,902 |
| Aadi Bioscience, Inc. | 1 | $3,750 |
| Eli Lilly and Company LLY | 3 | $3,719 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 1 | $3,683 |
| AstraZeneca Pharmaceuticals LP AZN | 2 | $2,735 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.